{"id":340,"date":"2024-11-05T17:18:35","date_gmt":"2024-11-05T17:18:35","guid":{"rendered":"https:\/\/admit:8890\/home\/"},"modified":"2026-03-18T11:27:28","modified_gmt":"2026-03-18T11:27:28","slug":"home","status":"publish","type":"page","link":"https:\/\/admit-therapeutics.com\/en\/","title":{"rendered":"Home"},"content":{"rendered":"\n

Technological Innovation and Social Commitment<\/h2>\n\n\n\n

ADmit Therapeutics S.L. is a pioneering company in the application of innovative technologies in the field of neurodegenerative diseases, with a strong social component. Its main asset is a highly trained team with experience in medical diagnostics, neurobiology, artificial intelligence, and the development and marketing of medical devices. Its quality is demonstrated by the clearance of the manufacturing license from the Spanish Agency of Medicines and Medical Devices (AEMPS), the ISO 13485 certification, the laboratory accreditation from the College of American Pathologists (CAP), and the Clinical Laboratory Improvement Amendments (CLIA) certificate, becoming the first Spanish CAP\/CLIA laboratory.<\/p>\n\n\n\n

The MAP-AD\u00ae Test<\/strong> is certified with the CE Mark under the In Vitro Diagnostic Regulation (IVDR, EU 2017\/746)<\/strong>, ensuring that the test complies with the European Union’s strict safety and performance standards. In addition to the development and commercialization of the MAP-AD\u00ae, the company continues to work on incorporating new solutions in the field of neurodegenerative diseases to improve the quality of life for patients and their families.<\/p>\n\n\n\n

<\/h2>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\n
\n
\n
\n<\/i>\n<\/div>\n\n\n\n
\n

Innovation<\/h2>\n\n\n\n

Our team has an innovative vision that has allowed us to develop a disruptive approach to the market.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n
\n<\/i>\n<\/div>\n\n\n\n
\n

Efficiency and Effectiveness<\/h2>\n\n\n\n

We optimize our resources to achieve each of our scientific and business objectives.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

\n
\n
\n<\/i>\n<\/div>\n\n\n\n
\n

Agility<\/h2>\n\n\n\n

We adopt agile and solid decisions to achieve our goals within the agreed timeframe.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

A crucial step towards personalized medicine<\/h2>\n\n\n\n

The MAP-AD\u00ae test provides a prognosis for the progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. This solution links disease biology, mitochondrial dysfunction, with cognitive changes. This is achieved through the analysis of novel blood biomarkers, mitochondrial DNA methylation, along with key disease risk factors (ApoE genotype and age), and neuropsychological assessment. Predicting cognitive decline years in advance opens the door to earlier interventions and optimizes patient selection for clinical trials, representing a significant advance in personalized and precision medicine.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n

Lastest news<\/h2>\n\n\n\n
<\/div>\n\n\n